💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pravastatin

CHEMBL1144 Phase 4 معتمد Small molecule
Half-Life
1.8 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
424.5 g/mol
LogP
1.6
Phase
4

A statin medication used to lower elevated cholesterol and triglyceride levels in the blood, reducing the risk of heart attacks, strokes, and the need for heart procedures. It is generally well tolerated and has fewer drug interactions than some other statins.

الوزن الجزيئي

424,5280 g/mol

LogP

1,60

TPSA

124,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Endometriosis Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Alzheimer's Disease Schizophrenia Melanoma Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Stroke Hyperlipidemia Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Heart Failure Prostate Cancer Colorectal Cancer Leukemia

تصنيفات الأدوية

C — C - Cardiovascular System

آلية العمل

Competitive inhibitor of HMG-CoA reductase.

Pharmacokinetics (PK)

Half-Life 1.8 hours

Pharmacodynamics (PD)

الآلية

Competitive inhibitor of HMG-CoA reductase.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21

                

                

                
                

                    
InChI

                    
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H36O7

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
الروابط القابلة للدوران

                        
11

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
30

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HMGCR (HMG-CoA Reductase)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Pravastatin + Fluconazole
                            
                        

                        
                        
Fluconazole has minimal effect on pravastatin exposure because pravastatin is not significantly metabolised by CYP enzymes; the interaction is pharmacokinetically unimportant in most patients.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Pravastatin + Colchicine
                            
                        

                        
                        
Concurrent use of colchicine and pravastatin carries a small theoretical risk of myopathy, as both drugs individually can cause muscle toxicity, though the combination is better tolerated than colchicine with …

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Pravastatin + Cyclosporine
                            
                        

                        
                        
Cyclosporine inhibits OATP1B1/1B3 hepatic transporters and P-glycoprotein, substantially increasing pravastatin plasma concentrations and raising the risk of myopathy and rhabdomyolysis.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A statin medication used to lower elevated cholesterol and triglyceride levels in the blood, reducing the risk of heart attacks, strokes, and the need for heart procedures. It is generally well tolerated and has fewer drug interactions than some other statins.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive inhibitor of HMG-CoA reductase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Pravastatin: Half-life: 1.8 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Pravastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1144.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 54687.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.